Genetic predictors of GLP1 receptor agonist weight loss and side effects - PubMed
3 hours ago
- #GLP1 receptor agonists
- #precision medicine
- #genetic predictors
- GLP1 receptor agonists like semaglutide and tirzepatide show significant inter-person variability in weight loss efficacy and side effects.
- A genome-wide association study (GWAS) of 27,885 individuals identified a missense variant in GLP1R associated with increased efficacy, predicting an extra -0.76 kg weight loss per effect allele copy.
- Variations in GLP1R and GIPR are linked to nausea or vomiting side effects, with the GIPR association specific to tirzepatide users.
- The findings enable patient stratification by efficacy and side effect risk, supporting precision medicine approaches for obesity treatment.
- The study was conducted by authors affiliated with 23andMe, highlighting potential conflicts of interest due to employment ties.